MedTrace Logo

VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans

NCT04805931 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4311

Last updated 2021-06-28

No results posted yet for this study

Summary

This is a prospective, randomized controlled trial that will evaluate the effectiveness of two different targeted outreach interventions aimed at increasing Covid-19 vaccine uptake. Veterans who are eligible for COVID-19 vaccine receipt by priority status (based on institutional guidelines) will be identified. Veterans must be enrolled into Veterans Health Administration (VHA) care and meet age or illness institutional priority guidelines to be eligible. Veterans eligible for enrollment into the trial will be randomized in a 1:1:1 allocation at an individual level, using permuted block randomization (with random block sizes of 3 and 6) to the following interventions:

1. Control arm - receives a text message with standard messaging
2. Arm 2 - receives a text message with a message framed for scarcity
3. Arm 3 - receives a text message with a message framed for improving the social good

Conditions

  • Covid19
  • Vaccine Refusal

Interventions

BEHAVIORAL

Behavioral economics

Tailored behavioral economic text messaging vs. standard text messaging

Sponsors & Collaborators

  • VA Puget Sound Health Care System

    lead FED

Principal Investigators

  • Ashok Reddy, MD, MS · VA Puget Sound

  • Karin Nelson, MD, MSHS · VA Puget Sound

  • Linnaea Schuttner, MD, MD · VA Puget Sound

  • Stefanie Deeds, MD · VA Puget Sound

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2021-05-01
Completion
2021-11-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04805931 on ClinicalTrials.gov